news

  • 5 August 2019
    Sienna Biopharmaceuticals Engages Cowen To Explore Financial And Strategic Alternatives

    Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives to maximize shareholder value. With Cowen's assistance, Sienna will continue to explore capital raising to enable the initiation of its planned Phase 3 pivotal clinical trials for SNA-120 (pegcantratinib), in addition to exploring a wide range of financial and strategic alternatives. Sienna does not intend to initiate its planned Phase 3 trials of SNA-120 until the Company secures sufficient additional capital.

    No assurance can be given as to whether any particular financial or strategic alternative will be recommended or undertaken and, if so, upon what terms and conditions.